Johnson & Johnson is a general drug manufacturer company located in New Jersey, United States, which is part of the Healthcare sector, and is traded under the ticker JNJ on the NYSE exchange.
Johnson & Johnson stock last closed at $176.64, up 1.1% from the previous day, and has increased 11.03% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.24 percentage points. Johnson & Johnson stock is currently +25.56% from its 52-week low of $140.68, and -0.35% from its 52-week high of $177.27.
As of Aug 15, 2025, there are 2.41B shares of JNJ outstanding. The market capitalization of JNJ is $425.41B. In the last 24 hours, 9.48M JNJ shares were traded.
You need a brokerage account in order to access the NYSE market and buy JNJ stock.
Based on our analysis, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of stock by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected the best brokerage, you'll need to fill out some personal details so you can invest in JNJ stock today.
Now that you've filled out your info on one of the best stock trading apps, you can securely and quickly fund your account:
Watch the video below if you need help transferring money into your brokerage account.
After you have identified the best place to buy Johnson & Johnson stock, it's crucial to evaluate their stock before you buy, so you truly comprehend the risk as well as the upside.
WallStreetZen was created to help average investors perform better fundamental analysis.
You can see all of the due diligence checks on JNJ's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge JNJ's fair value.
Using relative valuations measures:
You can do more valuation analysis on JNJ's stock here.
Out of 9 sell side analysts who track JNJ, the consensus analyst rating on JNJ is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Tim Anderson, a top 29% analyst from Bank of America maintains JNJ with a hold rating and raises their JNJ price target from $161.00 to $175.00, on Jul 17, 2025.
Bank of America's Tim Anderson raised their price target on Johnson & Johnson (NYSE: JNJ) by 8.7% from $161 to $175 on 2025/07/17. The analyst maintained their Hold rating on the stock.
Johnson & Johnson reported its Q2 2025 earnings.
Anderson told readers that their adjusted price target is still based on a sum-of-the-parts valuation, but is now using FY 2026 EPS estimates adjusted to account for the quarter's EPS beat and management's raised FY 2025 guidance.
For Q2 2025, Johnson & Johnson reported:
For FY 2025, management guided:
Chairman & CEO Joaquin Duato commented: “Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating across both MedTech and Innovative Medicine.
“Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways.”
David Risinger, a top 10% analyst from Leerink Partners downgrades JNJ to a hold rating and lowers their JNJ price target from $169.00 to $153.00, on May 13, 2025.
Jayson Bedford, a top 14% analyst from Raymond James maintains JNJ with a buy rating and raises their JNJ price target from $162.00 to $164.00, on Apr 16, 2025.
Asad Haider, a bottom 45% analyst from Goldman Sachs upgrades JNJ to a strong buy rating and raises their JNJ price target from $157.00 to $172.00, on Apr 9, 2025.
You can dig deeper into what analysts are projecting on the Johnson & Johnson stock forecast page.
Last year, JNJ earnings were $22.66B. In the past 5 year, JNJ's earnings have gone up by 10.24% per year. This was faster than the Drug Manufacturers - General industry average of 5.86%.
Last year, JNJ revenue was $90.63B. In the past five year, JNJ's revenue has increased by 2.4% per year. This was slower than the Drug Manufacturers - General industry average of 9.77%.
Dive into JNJ's earnings and revenue performance here.
In the last year, insiders at JNJ have sold more shares than they have bought.
John C. 1. Reed, EVP Innovative Medicine RD of JNJ, was the latest JNJ insider to sell. They sold $3,129,837.21 worth of JNJ stock on Jul 17, 2025.
Learn more about who owns JNJ shares here.
Johnson & Johnson pays a dividend of 2.84%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.91%. If you owned $1,000 worth of JNJ stock, you would have been paid $28.42 last year.
Johnson & Johnson dividend payments have consistently grown over the past decade and have remained stable.
Get more info about Johnson & Johnson dividend yield and history here.
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
You have two main options:
Click the Open Trade button and your broker will place the order.
If you require more help with buying stocks on eToro, watch the helpful video below:
Now that you own some JNJ stock, you'll want to stay up-to-date on your investment.
Create a watchlist to track your JNJ stock.
To summarize, here are the 6 steps for buying Johnson & Johnson stock:
If you require a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to monitor your investment in Johnson & Johnson, get started below.